Anebulo furnishes Part B final data charts for ANEB-001 Phase 2 trial, consistent with prior results

Anebulo Pharmaceuticals, Inc.

Exhibit 99.1 contains graphical charts of Part B final data from Phase 2 trial of ANEB-001 for acute cannabinoid intoxication.
Data shown is consistent with results reported in the March 28, 2023 Form 8-K.
Trial was randomized, double-blind, placebo-controlled in healthy volunteers challenged with oral delta-9-THC.
No new clinical findings or updated guidance are provided in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.